Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912691 · ClinicalTrials.gov registry record · Phase 3
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase 3 study, sponsored by Curemark.
- Completed
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT00912691 is a Phase 3 study that has completed, run by Curemark. The registered enrollment target is 165 participants.
The verdict
NCT00912691, a Phase 3 study, has completed, sponsored by Curemark.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CM-AT is effective in treating the core symptoms of autism.
Interventions
- DRUG CM-AT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2010-01 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912691
The ClinicalTrials.gov registry entry for NCT00912691 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curemark, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CM-AT is the first listed.
NCT00912691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912691 about?
NCT00912691 is a clinical study titled "A Trial of CM-AT in Children With Autism- Open Label Extension Study". The purpose of this study is to determine whether CM-AT is effective in treating the core symptoms of autism.
What is the current status of trial NCT00912691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2010-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00912691?
The interventions under investigation include: CM-AT (DRUG).
Who is sponsoring clinical trial NCT00912691?
This trial is sponsored by Curemark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.